Stem Cell Stocks
17283 views
Rate Now: 1 2 3 4

average rating: 4.00 / 2 ratings
Created by Guest
DESCRIPTION:

Date updated:11-01-2006

Here is a portfolio of stem cell stocks that could be interesting depending on which party wins in the mid term elections.

symbol name last price % change open
  • +
  • GERN
    Geron Corporation
  • $5.48
  • +0.37%
  • $5.39

Geron Corporation operates as a biopharmaceutical company and intends to use human embryonic stem cell technology to enable the development of transplantation therapies by providing starting material for the manufacture of cells and tissues.

People owning GERN also tend to own: CELGSTEMACTC.OBALXNARIAASTMCRIS

TheStreet.com Rating: D What is this?

  • +
  • ASTM
    Aastrom Bioscienc
  • $0.31
  • -3.12%
  • $0.3166

Aastrom Biosciences, Inc., a development stage company, focuses on the development of autologous cell products for use in regenerative medicine.

People owning ASTM also tend to own: ACTC.OBALXNARIACELGCRISDNDNGERN

TheStreet.com Rating: D- What is this?

  • +
  • STEM
    Stemcells
  • $1.13
  • -0.88%
  • $1.13

StemCells, Inc., a biopharmaceutical company, engages in the discovery and development of adult stem cell therapeutics to treat damage to; or degeneration of major organ systems, such as the central nervous system, liver, and pancreas.

People owning STEM also tend to own: CELGGERNABBCOMSFMOFXITDF

TheStreet.com Rating: D What is this?

  • +
  • VIAC
    Viac
  • $0.00
  • N/A
  • $N/A

ViaCell, Inc., a biotechnology company, engages in the research, development, and commercialization of cellular therapies in the United States and Singapore. It develops a pipeline of proprietary umbilical cord blood-derived and adult-derived stem cell product candidates as treatments for cancer, cardiac disease, and diabetes.

People owning VIAC also tend to own: ACTC.OBALXNARIAASTMCELGCRISDNDN

TheStreet.com Rating: No Rating What is this?

  • +
  • ACTC.OB
    Advanced Cell Tec
  • $0.0999
  • -0.10%
  • $0.0992

Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States.

People owning ACTC.OB also tend to own: DISFMOHDLOWPCLNPLUGWMT

TheStreet.com Rating: No Rating What is this?

  • +
  • IVGN
    N/a
  • $24.76
  • 0.00
  • $24.76

Invitrogen Corporation provides products and services that support academic and government research institutions, as well as pharmaceutical and biotechnology companies. The company operates in two segments, BioDiscovery and BioProduction. BioDiscovery segment offers functional genomics, cell biology, and drug discovery product lines. Functional genomics product line includes the research tools used in reagent and kit form for gene acquisition, gene cloning, gene expression, and gene analysis techniques.

People owning IVGN also tend to own: AGIXAVIDCTLMCVTXDSTIGLWINTV

TheStreet.com Rating: No Rating What is this?

  • +
  • ALXN
    Alexion Pharmaceu
  • $45.03
  • -0.35%
  • $44.73

Alexion Pharmaceuticals, Inc., a biotechnology company, together with its subsidiaries, engages in the discovery and development of biologic therapeutic products for the treatment of severe diseases in the United States.

People owning ALXN also tend to own: AVNRBCRXCORDCGNDSCOEXELFCEL

TheStreet.com Rating: B What is this?

  • +
  • LIFC
    Lifecell Corporat
  • $0.00
  • 0.00%
  • $N/A

LifeCell Corporation engages in the development and marketing of human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects.

People owning LIFC also tend to own: BMDCCJDVNGGBSONTSARXT

TheStreet.com Rating: B What is this?

previous next

Portfolio not tracked!

Comments not available

ADD YOUR COMMENTS:

Jim Cramer's Portfolios of the Week

By Roberto Pedone Posted on Nov. 6, 2009 According to Jim Cramer, the bears are tellinginvestors six lies. On Wednesday’s “Mad Money” TV show, Cramer said if you ...

11.06.09 | 15:52 PM
'Fast Money' Portfolios of the Week

By Roberto Pedone Posted on Nov. 5, 2009 The traders on CNBC’s “Fast Money” told their viewers what they must know after Warren Buffett announced on Tuesday his l...

11.05.09 | 12:05 PM
Squeezing the Shorts: Late Earni...

By Jonas Elmerraji Posted on Nov. 4, 2009 For investors who seek out short-squeeze opportunities, there’s no time as important as earnings season. Earnings are one of...

11.04.09 | 15:18 PM
Cramer's Take on Headline Stocks...

By Stockpickr Staff Posted on Nov. 4, 2009 Regardless of why a stock is in the news, it never hurts to hear what a professional investor has to say about it. The key is...

11.04.09 | 11:12 AM
more articles
The Presidential/Political Thread
01.02.08 | 08:05 AM From author Dave Cox
General market Technical Analysi...
11.14.07 | 22:55 PM From author ZA
Wealth distribution by race and ...
11.23.08 | 18:44 PM From author Valerie J
Full Disclosure
11.09.08 | 12:30 PM From author alchemist
more forums
Q. In the sprit of political neutra...
11.08.09 | 12:01 PM Asked by Brian Larson

A. i bought into ECLP last thursday. . They
compete with CERNER on putting in big
medical records systems into hospitals.
I believe the industry is going to
consolidate as well.

today 's lists
52-Week Highs

Here are some of the biggest stocks that made the 52-week high list on Nov. 2, 2009. more

Biggest % Losers

Here is the stock list of some of the largest % losers from Nov. 2, 2009. more

Analyst Downgrades

Analyst Downgrades for Nov. 2, 2009. Read more here. more